Skip to content

Intrexon sparks interest with 24% revenue growth, insect-based feed

May 11, 2017

After Intrexon (NYSE:XON), a company focused on synthetic biology, reported first-quarter earnings, its shares rose 18% as of 11:25 a.m. EDT on Thursday.

Here’s a review of the headline numbers from the quarter:

  • Revenue grew 24% to $53.7 million. That figure easily exceeded the $48.8 million in revenue that market watchers were looking for.
  • Net loss was $31.4 million, or $0.26 per share. That was a bit worse than the $0.23 loss that Wall Street had expected.
  • Cash balance at the end of the quarter was $205.2 million.

Financial numbers aside, Intrexon also had a slew of other recent developments to share with investors:

  • Intrexon and Darling Ingredients announced that their EnviroFlight joint venture will build a new commercial-scale production facility of insect-based feed ingredients for animal feed.
  • The company’s reported that its Friendly Aedes mosquitoes achieved greater than 80% suppression of wild Aedes aegypti in Brazil in the second year of the project.
  • Intrexon’s collaborating partner, Ziopharm Oncology (NASDAQ:ZIOP), reported a successful end-of-phase 2 meeting with the Food and Drug Administration for Ad-RTS-hIL-12 and veledimex in treating recurrent glioblastoma. A pivotal phase 3 trial is currently in the works.
  • Ziopharm also announced improved production times in its ongoing phase 1 trial of its second-generation Sleeping Beauty CD19 + CAR-T cells. In addition, a patient with multiple-relapsed acute lymphoblastic leukemia achieved a complete response and another patient with non-Hodgkin lymphoma was treated with T-cells manufactured by the company in just two weeks.
  • Intrexon and Ziopharm also had an IND application accepted by the FDA for a phase 1 study of the company’s CD33-specific CAR+ T therapy in refractory acute myeloid leukemia (AML). Enrollment is expected to begin next quarter.
  • The company announced the formation of a new subsidiary called Precigen that is designed to “accelerate strategic evaluation of structural alternatives for consolidation of Intrexon’s health-related assets to enhance shareholder value and maximize the potential of the Company’s programs in health.”
  • Intrexon and partner Fibrocell Science announced fast-track designation from the FDA for FCX-007 for the treatment of recessive dystrophic epidermolysis bullosa.
  • Intrexon agreed to acquire GenVec.
  • Intrexon completed the listing of its AquaBounty Technologies subsidiary on the Nasdaq.


Intrexon continues to offer investors multibagger potential if any of its high-risk projects pay off. However, keeping tabs on all of those projects can be quite difficult, which makes this a stock that requires a tremendous amount of homework. For that reason, this stock should probably only be owned by seasoned investors who are comfortable with volatility.


From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: